Empresa Pluristem Therapeutics Inc. Nasdaq
Acciones
US72940R1023
Biotecnología e investigación médica
Resumen de negocios
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Placenta-Based Cell Therapy
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +22,65 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Israel
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +22,65 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 52 | 01/11/06 |
Director of Finance/CFO | 40 | 01/05/13 | |
Zami Aberman
CHM | Chairman | 70 | 26/09/05 |
Artur Machlenkin
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/22 |
Nitsan Halevy
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/21 |
Lior Raviv
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/11 |
Orly Amiran
PRN | Corporate Officer/Principal | - | - |
Nimrod Bar Zvi
PRN | Corporate Officer/Principal | - | - |
Efrat Kaduri
PRN | Corporate Officer/Principal | - | 01/10/14 |
Human Resources Officer | 62 | 01/01/07 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Director/Board Member | 73 | 15/07/21 | |
Lorne Abony
BRD | Director/Board Member | 55 | 11/07/23 |
Zami Aberman
CHM | Chairman | 70 | 26/09/05 |
Yaky Yanay
CEO | Chief Executive Officer | 52 | 01/11/06 |
Director/Board Member | 54 | 06/01/21 | |
Director/Board Member | 61 | 01/06/21 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 5 388 792 | 4 101 934 ( 76,12 %) | 0 | 76,12 % |
Información de la empresa
Pluri, Inc.
MATAM Advanced Technology Park Building No. 5
3508409, Haifa
+972 74 710 8600
http://www.pluri-biotech.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+17,96 % | 44,96 mil M | |
+1,17 % | 42,65 mil M | |
+48,77 % | 41,85 mil M | |
-4,27 % | 29,04 mil M | |
+11,42 % | 26,08 mil M | |
-21,39 % | 19,03 mil M | |
+4,86 % | 12,75 mil M | |
+27,29 % | 12,06 mil M | |
-3,50 % | 11,75 mil M |